The multidrug resistance proteins (MRPs) MRP1, MRP2, MRP3, MRP5 and P-glycoprotein (P-gp) act in concert with each other to give a net resultant pump function in acute myeloid leukemia (AML). The aim of the present study was to analyze the activity of these proteins, which might be upregulated at relapse as compared with de novo AML due to clonal selection. The mRNA expression and activity of P-gp and the MRPs were determined with RT-PCR and flow cytometry, in conjunction with phenotype, as measured with the monoclonal antibodies CD34, CD38 and CD33, in 30 paired samples of de novo and relapsed AML. P-gp and MRP activity varied strongly between the cases (rhodamine 123 efflux-blocking by PSC833: 5.4 ؎ 7.7, and carboxyfluorescein efflux-blocking by MK-571: 4.3 ؎ 6.7, n ‫؍‬ 60). P-gp and MRP activity were increased in 23% and 40% of the relapse samples, and decreased in 30% and 20% of the relapse samples, respectively (as defined by a difference of Ͼ2 ؋ standard deviation of the assays). Up-or downregulation of mRNA expression was observed for MDR1 (40%), MRP1 (20%), MRP2 (15%), MRP3 (30%), and MRP5 (5%). Phenotyping demonstrated a more mature phenotype in 23% of the relapsed AML cases, and a more immature phenotype in 23% of the relapses, which was independent of the karyotypic changes that were observed in 50% of the studied cases. P-gp and MRP activity correlated with the phenotypic changes, with higher P-gp and MRP activities in less mature cells (r ‫؍‬ −0.66, P Ͻ 0.001 and r ‫؍‬ ؊0.31, P ‫؍‬ 0.02, n ‫؍‬ 58). In conclusion, this study shows that P-gp and MRP activity are not consistently upregulated in relapsed AML. However, P-gp and MRP activities were correlated with the maturation stage as defined by immune phenotype, which was observed to be different in 46% of the relapses. Leukemia (2001) 15, 1544-1553.
Introduction
The overexpression of ATP-binding cassette (ABC) membrane transporters that function as drug efflux pumps has been identified as an important cause of treatment failure in acute myeloid leukemia (AML). [1] [2] [3] [4] [5] [6] These include the ABC transporters P-glycoprotein (P-gp), 7, 8 encoded by the multidrug resistance 1 gene (MDR1), which is located on chromosome 7q21, and the multidrug resistance protein 1 (MRP1), 9 encoded by the MRP1 gene, located on chromosome 16p13. The simultaneous functional expression of P-gp and MRP1 has been shown to be correlated with poor overall survival in AML. [10] [11] [12] The transport kinetics of anthracyclines by P-gp and MRP1 are rather similar. 13 An important difference between P-gp and MRP1 is that MRP1 transports cationic and neutral compounds only in the presence of glutathione (GSH).
MRP3 has been shown to pump methotrexate and etoposide, but not GSH; 21 MRP4 has been described to confer resistance to methotrexate after short-term exposure, and to 9-(2-phosphonylmethoxethyl)-adenine (PMEA) 22 and azidothymidine; 23 while MRP5 was found to transport 6-mercaptopurine, 24, 25 which is also used in the palliative treatment of AML. [26] [27] [28] MRP6 and MRP7 have not yet been found to play a role in multidrug resistance. 18, 19 Patients with AML are treated with intensive chemotherapy regimens, including daunorubicin, idarubicin, etoposide and mitoxantrone, which are substrates for the multidrug resistance (MDR) proteins. These induction chemotherapy regimens result in a first complete remission (CR) rate of 60-70%. [29] [30] [31] However, despite the intensive regimen, a considerable number of AML patients show resistance to the treatment or relapse after CR and eventually die from their disease, which results in a 5 year disease-free survival of 25-35%. [32] [33] [34] [35] Little is known about the expression and function of P-gp and the MRPs in refractory and relapsed state AML patients. In some studies MDR1 or MRP1 mRNA expression have been described to be upregulated in relapsed or refractory AML vs AML at diagnosis, [36] [37] [38] whereas in other studies no distinct differences were observed. 38, 39 So far, no data have been published concerning the functional activity of P-gp and MRP and mRNA expression of the MRP1 homologues in de novo vs relapsed state AML. In the present study, our interest was to analyze the functional activity of P-gp and the MRPs (MRP1, MRP2 and MRP3), that act in concert with each other to give a net resultant pump function, which might be upregulated at relapse as compared with the primary AML due to clonal selection or to intrinsic defects of the AML cells.
A few large studies have described changes in karyotype between diagnosis and relapse in AML, 40, 41 in which less complex or more complex karyotypes were observed at relapse. We have described a correlation between the lack of MRP activity and the occurrence of MRP1 deletions in AML patients with an inversion on chromosome 16 in a previous study. 42 We therefore determined in the present study the karyotype of the AML patients at diagnosis and at relapse, with emphasis on the chromosomal loci 16p13 and 7q21, on which MRP1 and MDR1 are located. Thirty paired samples of de novo and refractory or relapsed state AML were studied. P-gp and MRP activity were determined with a flow cytometric assay. MDR1, MRP1, MRP2, MRP3 and MRP5 mRNA expressions were measured by means of reverse transcriptasepolymerase reaction (RT-PCR). Since it has been described that P-gp expression and function are correlated with the maturation stage of AML cells, 12, 43 we also measured the expression of the monocolonal markers CD33, CD34 and CD38.
Patients, materials and methods

Patients
After informed consent, bone marrow aspirates or peripheral blood were collected from AML patients at the time of diagnosis and relapse between July 1992 and April 2000 at the University Hospital Groningen and Free University Hospital Amsterdam. Patients were classified at presentation of the disease according to the French-American-British (FAB) classification. 44 Leukemic blasts were enriched by Ficoll-Isopaque (Nycomed, Oslo, Norway) density gradient centrifugation, cryopreserved in RPMI 1640 medium (Bio Whittaker, Brussels, Belgium) supplemented with 10% fetal calf serum (FCS) (Hyclone, Logan, UT, USA) and 10% dimethyl sulfoxide (DMSO) (Merck, Amsterdam, The Netherlands), and stored at −196°C. For the present study paired cases, which were available at the time of diagnosis as well as at relapse, were selected. Upon analysis, AML blasts were thawed, treated with DNAse (Boehringer Mannheim, Almere, The Netherlands), washed with RPMI 1640 medium, and incubated for 30 min in RPMI 1640 medium, supplemented with 10% FCS at 37°C, 5% CO 2 . If more than 10% T cells were present, as determined by the percentage of CD3-positive cells, T lymphocytes were depleted by 2-aminoethylisothiouronium bromidetreated sheep red blood cell (SRBC) rosetting. T cell-SRBC rosettes were removed by Ficoll-Isopaque density gradient centrifugation. May-Grü nwald Giemsa staining was performed to determine the percentage of blast cells in the AML cells, and in all cases the percentage of blast cells was Ͼ90%.
Detection of functional drug efflux in combination with CD34 expression
Functional activity of the P-gp and MRP transporter proteins was demonstrated as described previously. 45 To analyze P-gp activity we used rhodamine 123 (Rh123) (Sigma Chemical, Bornem, Belgium) in combination with the P-gp-specific inhibitor PSC833 (provided by Novartis Pharma, Basel, Switzerland). To determine MRP (MRP1 and homologues MRP2 and probably MRP3) activity the compound carboxyfluorescein diacetate (CFDA) was used, which permeates the plasma membrane and upon cleavage of the ester bonds is transformed into the fluorescent anion CF. The leukotriene D4 receptor antagonist and MRP inhibitor MK-571 46 was used to inhibit CF efflux. Cells (0.5 × 10 6 ) were loaded for 20 min at 37°C, 5% CO 2 with 0.1 m CFDA or 200 ng/ml Rh123 with or without inhibitor (20 m MK-571 or 2 g/ml PSC833) in RPMI 1640 medium. Thereafter cells were washed in ice-cold medium and incubated for 1 h in drug-free medium with or without inhibitor at 37°C, 5% CO 2 . Efflux was stopped by pelleting the cells and adding ice-cold medium. Thereafter cells were either incubated for 30 min on ice, or labeled with a APClabeled monoclonal antibody CD34 (IQ Products, Groningen, The Netherlands), incubated for 30 min on ice and washed with ice-cold medium. CF, Rh123 and APC fluorescence of 5000 events were measured with a FACScalibur flow cytometer. The efflux-blocking factors of the inhibitors in CD34 − cells, CD34 + cells, or in the whole cell population, were expressed as the median relative fluorescence units (FU) in inhibitor blocked cells divided by the median relative FU in unblocked cells after 60 min. To determine the reproducibility of the assay, the P-gp and MRP activities were measured three Leukemia times in some AML patient samples. Based on these results the s.d. of the assay was determined, and up-or downregulation at relapse vs the primary samples was defined as a difference of Ͼ2 × s.d. of the assay. For ␤-2 microglobulin PCR, which was performed as an internal standard, primers were: sense: 5ЈCCAGCAGA GAATGGAAAGTC3Ј, antisense: 5ЈGATGCTGCTTACATG TCTCG3Ј; the amplified product consisted of 268 bp.
RNA extraction and RT-PCR
The PCR reactions were subjected to the following cycle numbers of, respectively, denaturation (95°C, 30 s), annealing (55°C for MDR1 and MRP5, 56°C for MRP1, MRP3 and ␤-2 microglobulin, 58°C for MRP2, 30 s and extension (72°C, 30 s, MDR1 and MRP2: 31 cycles, MRP1 and MRP5: 29 cycles, MRP3: 32 cycles and ␤-2 microglobulin: 20 cycles.
Reaction products (5 l) were separated on a 1.5% agarose gel in Tris-acetate-EDTA (TAE) buffer. The PCR reaction product bands were visualized by ethidium bromide staining. Densitometric scanning was performed with a Image Master VDS (Pharmacia, Woerden, The Netherlands), and optical density (OD) was expressed as OD × mm 2 using the program Diversity One 1D (PDI, New York, NY, USA). The band density of each mRNA product in a patient sample at diagnosis was compared with the density of the band at relapse.
To determine the reproducibility of the RT-PCR assay of the ␤-2 microglobulin, MDR1, MRP1, MRP2, MRP3 and MRP5 genes, the RT-PCR reaction of each gene was performed six times in three independent AML samples. The absorbance of the bands was measured and the standard deviation (s.d.) and the 95% confidence interval of the assay was calculated.
Maturation stage
To determine the maturation stage of the AML blasts, phenotyping was performed using monoclonal antibodies against CD34 in combination with CD38 or CD33, or immunoglobulin G isotype-matched controls (Becton Dickinson, Mountain View, CA, USA). 0.5 × 10 6 Cells were incubated with 5 l of fluorescein isothiocyanate-or phycoerythrin-labeleled mouse monoclonal antibodies for 20 min at 4°C, washed with RPMI 1640 medium, and analyzed with a FACScalibur flow cytometer (Becton Dickinson Medical Systems, Sharon, MA, USA).
The percentages of the following subclasses of cells were determined: CD34 + cells as the mature population. The reproducibility of the assay was determined by measuring the percentage of the different subclasses three times in some patient samples. Based on these results, the s.d. of the assay was calculated and up-or downregulation of a specific subclass at relapse vs the primary sample was defined as a difference of Ͼ2 × s.d. of the assay. A maturation status of the cells was calculated using the following formula:
+ resulting in a maturation status between 0 and 3, 0 representing the most immature and 3 representing the most mature subclass. The s.d. was calculated and a difference in maturation status between primary and relapse was defined as a difference of Ͼ2 × s.d. In the patient samples in which no CD34 + /CD38 − percentage could be determined, the maturation stage was calculated using the CD34
+ and CD34 − /CD33 + percentages.
Cytogenetics
Bone marrow or peripheral blood cells from primary as well as relapsed samples were cultured for 24 and 48 h in RPMI 1640 supplemented with 15% FCS. The cultures were harvested and chromosome preparations were made according to standard cytogenetic techniques. The chromosomes were G-banded using trypsin or pancreatin, and karyotypes were described according to the International System for Human Cytogenetic Nomenclature (ISCN) 1995.
Statistical analysis
The Mann-Whitney U and Wilcoxon non-parametric tests were used to calculate significant differences, and correlations were calculated using the Spearman bivariate nonparametric correlation test. Data were expressed as mean ± s.d. P values Ͻ0.05 were considered significant.
Results
Patient characteristics
Paired bone marrow and peripheral blood samples were collected from 30 AML patients at diagnosis and relapse or complete remission (CR), five patients reached partial remission (PR), defined as Ͻ25% of AML blasts in the bone marrow smear, and two patients were refractory to the treatment and did not reach remission. Patient characteristics are described in Table 1 .
P-gp activity, MRP activity and CD34 expression
To study whether P-gp or MRP activity was upregulated at relapse as compared with de novo AML cases, we determined the activity of the transporter proteins in 30 paired samples. Since it has been described that the functional activity of Pgp is related to the expression of CD34, 45 we performed the P-gp and MRP functional assay in combination with the measurement of CD34 expression.
The functional activity of P-gp in the whole blast population Leukemia demonstrated a great variability in efflux-blocking factors. Rh123 efflux-blocking factors of PSC833 varied between 0.9 and 42.4 (5.4 ± 7.7, mean ± s.d., n = 60). A difference in efflux-blocking factor of Ͼ26% (= 2 × s.d. of the assay) between primary and relapsed samples was considered significant. The P-gp activity was upregulated in seven relapsed cases and downregulated in nine relapsed cases as compared with the primary samples. The P-gp activity in the whole group of relapsed samples (5.8 ± 9.0, n = 30) did not differ from the whole group of diagnosis samples (5.0 ± 6.2, n = 30, P = 0.54). However, the P-gp activity in CD34
− cells was lower than in CD34
+ cells (efflux-blocking factors of 1.5 ± 0.7, n = 54, vs 7.4 ± 9.4, n = 54, P Ͻ 0.001). An example of Pgp activity in CD34
− vs CD34 + cells (patient No. 19 ) is shown in Figure 1 .
MRP activity also showed a great variability in the whole blast population. CF efflux-blocking factors of MK-571 varied between 0.8 and 42.8 (mean 4.3 ± 6.7, n = 60). MRP activity was increased (as defined by a difference of Ͼ20% (= 2 × s.d. of the assay) in 12 relapsed cases and decreased in six cases as compared with the primary samples. The MRP activity of the whole group of relapsed and refractory patients did not differ from the whole group of primary samples, namely 4.6 ± 7.5 (n = 30), vs 4.0 ± 5.9 (n = 30, P = 0.3). CF efflux-blocking factors of MK-571 were higher in the CD34 + compartment (5.0 ± 7.0, n = 56) than in the CD34 − compartment (2.7 ± 1.8, n = 55, P Ͻ 0.001). The P-gp and MRP activities of the individual patients are shown in Figure 2 . P-gp and MRP activity in primary and relapsed AML patients. P-gp and MRP activities, expressed as Rh123 efflux-blocking factors of PSC833 and CF efflux-blocking factors of MK-571, respectively, are presented in the whole blast population (a and d), in the CD34 − compartment (b and e) and in the CD34 + compartment (c and f), at presentation and at relapse of the AML.
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MDR1, MRP1, MRP2, MRP3 and MRP5 mRNA expression
To test whether the differences in P-gp and MRP activity between primary and relapsed state AML patient samples were correlated with the mRNA expression of MDR1 and MRP1, MRP2 and possibly MRP3, a semiquantitative RT-PCR analysis was performed. The relative mRNA expressions of these MDR genes, and of MRP5, as compared to that of ␤-2 microglobulin were calculated. RT-PCR analysis was possible in 18 paired samples. For each AML patient the difference between the value at diagnosis vs the relapsed or refractory sample was expressed. The results are presented in Figure  3a -e.
MDR1 mRNA, as depicted in Figure 3a , is upregulated in relapsed vs diagnosis samples in five cases, whereas in three cases it is downregulated; 10 patient cases showed no difference. The up-or downregulation of MDR1 mRNA correlated well with the up-or downregulation of P-gp activity (r = 0.58, P = 0.01, n = 18) in the relapsed vs the primary samples.
The differences between primary and relapsed samples of MRP1, MRP2, MRP3 and MRP5 mRNA expressions are depicted in Figure 3b -e, and showed a heterogenous pattern. MRP1 mRNA expression at relapse was upregulated in only one case and showed a reduced expression in three cases, MRP2 mRNA expression was upregulated in three relapsed cases. Considering MRP3 mRNA, an increased expression was observed in three cases and a reduced expression was 
Maturation stage
Since we found a strong correlation between the P-gp and MRP activities and the expression of CD34, we were interested whether a correlation could be observed between the pump function and the differentiation stage of the AML samples as measured by immune phenotype, with a combination of the monoclonal markers CD34, CD38 and CD33. Cells that were CD34-positive and CD38-negative (CD34 
/CD33
+ cells was higher in nine and lower in 11 relapsed cases as compared to the primary cases. The results are presented in Table 2 .
Since these findings might implicate a shift in the maturation stage, due to the occurrence of a new clone, the maturation status of the AML blasts was calculated, ranging from 0 to 3, 0 representing the most immature cell population, and 3 representing the more mature cell population. A difference of Ͼ9.6% (2 × s.d.) between relapsed and primary samples was considered significant. In seven cases the maturation status represented a more immature character and in seven cases the maturation status represented a more mature character at relapse (Figure 4) . A correlation was observed between the percentage of CD34
− cells and P-gp as well as MRP activity (r = 0.28, P = 0.04, n = 55, and r = 0.44, P = 0.001, n = 55, respectively). In addition, a correlation was found between CD34 positivity and P-gp activity (r = 0.51, P Ͻ 0.001, n = 59). A strong negative correlation was observed between the percentage of the more mature CD33
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Figure 4
Maturation status in primary and relapsed AML patients. The calculated maturation status of 30 AML patients at the time of diagnosis (᭹) and at relapse (᭺), 0 representing the most immature and 3 representing the most mature status. nd, not done. changes in pump activity, observed in the relapsed AML samples, were dependent on the changes in maturation stage.
Karyotype
To examine whether the changes in maturation status and in P-gp and MRP activities between primary and relapse cases were reflected by changes in karyotype, cytogenetic analysis was performed in 29 patient samples at presentation and was possible in 16 samples at relapse. Four patients had a normal karyotype at the time of diagnosis as well as at relapse, and Table 3 Correlations between immune phenotypic subclasses and P-gp and MRP activity The results represent correlation coefficients between the percentages of the different immune phenotypic subclasses, and P-gp and MRP activity, expressed as Rh123 efflux-blocking factors of PSC833 and CF efflux-blocking factors of MK-571, respectively; P values are presented in parentheses, significant correlations are presented in bold.
four patients had a karyotype showing the same clonal chromosomal abnormalities at both time points. However, eight AML patients demonstrated chromosomal clones at relapse, which were different from the time of diagnosis. Three of these patients showed a normal karyotype at diagnosis and various clonal chromosomal abnormalities at relapse (patient Nos 2, 4 and 5), three patients (Nos 7, 16 and 23) showed clonal devolution, presenting a chromosomal aberrant clone at diagnosis, which was not observed in the relapsed material, and in two patients (Nos 9 and 18) clonal evolution was observed, showing additional chromosomal abnormalities at relapse as compared with the primary AML (Table 4) . Since we have previously described a correlation between MRP activity and the occurrence of MRP1 deletions in AML patients with inversion 16, 33 we now focussed on chromosome 16p13, and chromosome 7q21, on which MDR1 resides. Patient No. 2 showed a translocation of chromosome 16p13 in the relapsed sample, not in the primary sample. However, no significant differences in MRP1 mRNA expression or MRP activity were observed in this patient sample. Two patients (Nos 8 and 17) showed an additon or derivative of chromosome 7q21. No correlations were observed between the differences in karyotype and P-gp or MRP activities, and between the differences in karyotype and maturation status.
Discussion
Several studies have described the poor prognostic value of P-gp, [1] [2] [3] [4] [5] [6] and to a certain extent MRP [10] [11] [12] in AML, which might imply a clonal selection of cells with high P-gp and MRP activity at the time of relapse. This is supported by some studies describing an upregulation of MDR1 or MRP1 mRNA in relapsed AML samples as compared to primary AML. [36] [37] [38] However, these findings were not confirmed by other studies. 38, 39 In the present study, we observed no consistent upregulation of MDR1, MRP1, -2, -3 or -5 mRNA expression in relapsed vs de novo AML cells. In addition, no consistent upregulation of P-gp or MRP functional activity was found at relapse. A distinct correlation was observed between P-gp activity and maturation stage of the AML blasts, and between MRP activity and maturation stage, with a higher P-gp or MRP activity in the less differentiated cells. This change in maturation stage was not a consistent finding in all relapsed cases; in 23% of the cases the relapsed AML blasts expressed a more mature phenotype, whereas in 27% the relapsed cells had become less mature. These changes might be related to the emergence of new karyotypic clones, which were observed in 50% of the studied cases. The karyotypic changes in the relapsed samples, which were also noticed in some larger studies, 40, 41 included variations on the chromosomes 7q21 and 16p13, on which MDR1 and MRP1 are located. However, we did not observe a correlation between changes in karyotype and the activity of the MDR genes, or between changes in karyotype and maturation, indicating that other intrinsic defects might exist, which lead to the phenotypic changes. MRP1 and MRP2 mRNA expression in AML blasts have been described earlier; 45 the expression of MRP3 and MRP5 mRNA in AML blasts is described here for the first time and demonstrated a variable expression, which could be increased or decreased at relapse vs diagnosis.
No correlations were observed between MRP activity, as measured by the CF efflux-blocking capacity of MK-571, and MRP1, -2, -3, or -5 mRNA expression. As described previously, MRP1 and MRP2 show the same substrate specificities 49, 50 and both have been found to transport CF. 45, 51 With regard to MRP3, which shows 58% amino acid identity with MRP1, it has been demonstrated that MRP3, in contrast to MRP1 does not transport GSH. 21 CF, however, is transported independently of GSH, 51 which makes it a potential candidate to be pumped by MRP3. MRP5 has been described to transport cyclic nucleotides 25 and the anticancer drugs 6-mercaptopurine and thioguanine. However, it is unlikely that MRP5 activity is measured in the flow cytometric assay with CF and MK-571, since MK-571 does not inhibit the MRP5-mediated transport. 25 Furthermore, the observed discrepancy between the mRNA expressions and the MRP functional assay might be due to the different contribution of MRP1, MRP2, MRP3, and possibly other MRPs such as MRP4, MRP6 or MRP7, in the CF efflux assay.
We observed a correlation between the up-and downregulation of MDR1 and MRP2 mRNA expression. Although a colocalization of both proteins has been reported, 51 a coregulation of MDR1 and MRP2 has not been described before. These findings suggest that interactions might exist between the different MDR transporter proteins. A similar observation was observed in AML patients with the chromosomal inversion 16; patients with deletion of MRP1 showed upregulation of other MRP genes. 42 Some studies have been conducted with PSC833 as sole MDR modifier in relapsed AML patients. 52, 53 Considering the results of the present study, which show a diversity of changes in MDR genes, it seems highly unlikely that one MDR modifier will overcome multidrug resistance in AML. Since P-gp as well as MRP has been described to transport substrates that are used in the treatment of AML, and the functional expression of both proteins is correlated with poor outcome, it seems more interesting to treat patients in the future with a combination of MDR inhibitors, or with chemotherapeutic agents that are not transported by the MDR drugs. In conclusion, this study shows that the P-gp and MRP activity depends on the maturation stage of the AML blasts, which can be different at relapse vs AML at diagnosis.
